【2h】

Therapy of leprosy

机译:麻风病的治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The latest developments and ideas in the therapy of leprosy are discussed, the need for long-term studies being stressed. The therapeutic efficacy and effective dosages of some sulfones (especially diaphenylsulfone), thiambutosine and long-acting sulfonamides such as sulfamethoxine and sulfalene, are considered. The possibilities for two newer drugs, 4,4′-diacetyldiaminodiphenylsulfone and clofazimine (B-663), both still in the early stages of evaluation, are also described and the potential value of thalidomide in treatment of the lepra reaction is discussed. The authors make a number of recommendations for controlled trials and lines of investigation and, in particular, favour a biochemical approach to the correction of defective host defences. Diaphenylsulfone is still considered the drug of choice for use in the therapy of leprosy.
机译:讨论了麻风治疗的最新进展和想法,并强调了长期研究的必要性。考虑了某些砜类(特别是二苯砜),噻虫丁和长效磺酰胺(如磺胺二甲嘧啶和环丁砜)的治疗功效和有效剂量。还描述了仍处于评估早期阶段的两种新药4,4'-二乙酰基二氨基二苯砜和氯法齐明(B-663)的可能性,并讨论了沙利度胺在治疗lepra反应中的潜在价值。作者为对照试验和研究方向提出了许多建议,特别是赞成采用生物化学方法纠正有缺陷的宿主防御。二苯砜仍然被认为是治疗麻风病的首选药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号